// App-Quantinova.ai

BSH2020‐PO‐106 : Phase Ib/II trial of polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed/refractory follicular lymphoma: primary analysis of the full efficacy population

Researchers

Presenter

  • C. S. Diefenbach

Principal Investigators

  • A. McMillan

  • B. S. Kahl

  • F. Miall

  • L. Banerjee

  • J. Briones

  • R. Cordoba

  • P. Abrisqueta

  • J. Hirata

  • Y. Chang

  • L. Musick

Medical Centers

  • Perlmutter Cancer Center NYU Langone, New York, NY

  • Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, United Kingdom

  • Washington University, St Louis, MO

  • University Hospitals Leicester NHS Trust, Leicester, United Kingdom

  • Oncology Centre, Maidstone and Tunbridge Wells NHS Trust, Kent, UK

  • Hospital Santa Creu i Sant Pau, Barcelona, Spain

  • Fundacion Jimenez Diaz University Hospital, Madrid, Spain

  • University Hospital Vall d'Hebron, Barcelona, Spain

  • Genentech, Inc., South San Francisico, CA

  • Hoffmann-La Roche Ltd, Mississauga, ON, Canada

  • Genentech, Inc., South San Francisico, CA

Locations

  • United States

  • United Kingdom

  • Spain

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Infectious Diseases (ID)

  • Oncology (ONC)

Disease

  • Follicular lymphoma

  • Thrombocytopenia

  • Septic shock

  • Neutropenia

  • Lymphomas

Biomarkers

  • B-lymphocyte antigen CD20

Drug/Treatment

  • Polatuzumab vedotin

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • Lenalidomide

Outcome

  • N/A

Study Design

  • Multinational

  • Multicenteric

  • Cohort

Phase

  • I

Study Id's

  • NCT02600897

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved